Shire PLC (SHPG.OQ)
24 Feb 2017
* No serious adverse events or discontinuations due to adverse events were observed at all doses studied
* GSK, AZ, Shire welcome update (Adds GSK statement, analyst comment, details)
LONDON Pharmaceuticals group Shire on Thursday said it was extremely optimistic about long-term growth after reporting a 12 percent rise in earnings for the past year in which it made its largest ever acquisition.
* Shares rise 6 pct (Adds CEO comments, analyst reaction, shares)
LONDON, Feb 16 Pharmaceuticals group Shire reported a 12 percent rise in full-year earnings after what it said was a transformational year marked by its largest acquisition to date, adding that it is extremely optimistic on long-term growth prospects.
A federal appeals court has removed a roadblock to the launch of a generic version of Shire PLC's bowel disease drug Lialda, reversing a lower court decision that the generic version would infringe Shire's patent.
WASHINGTON, Feb 7 The U.S. Federal Trade Commission filed a complaint against Shire ViroPharma on Tuesday, accusing it of hijacking a government channel designed to flag safety issues by using it to fend off generic competition, the agency said in a statement.
WASHINGTON The U.S. Federal Trade Commission filed a complaint against Shire ViroPharma on Tuesday, accusing it of abusing government processes in order to fend off generic competition to its antibiotic Vancocin HCl, the agency said in a statement.
WASHINGTON, Feb 7 The U.S. Federal Trade Commission filed a complaint against Shire ViroPharma on Tuesday, accusing it of abusing government processes in order to fend off generic competition to its antibiotic Vancocin HCI, the agency said in a statement.
* U.S. FDA acknowledges receipt of Shire's new drug application for SHP465 for ADHD
|Novartis AG (NOVN.S)||CHF77.60||0.00|
|Eli Lilly and Co (LLY.N)||$82.87||+0.32|
|Catalyst Biosciences Inc (CBIO.OQ)||$6.12||-0.17|
|Abbott Laboratories (ABT.N)||$45.68||+0.28|
|Actelion Ltd (ATLN.S)||CHF269.80||+1.00|
|Supernus Pharmaceuticals Inc (SUPN.OQ)||$25.30||-0.05|
|Salix Pharmaceuticals, Ltd. (SLXP.OQ)||--||--|
|ARYx Therapeutics, Inc. (ARYX.PK)||$0.00||0.00|
|Innoviva Inc (INVA.OQ)||$11.48||-0.04|
|Sucampo Pharmaceuticals, Inc. (SCMP.OQ)||$11.75||+0.05|